The Induction and Characterization of a Potential Rough-Type Brucella Vaccine Candidate Strain RA343, and Its Safety, Protective Efficacy in Mouse and Guinea Pig Models

Abstract

Brucellosis is a zoonotic disease caused by Brucella spp. which seriously jeopardizes the health and safety of animals and human beings. Therefore, developing a live attenuated vaccine is a priority. In this study, a genetically stable Brucella rough RA343 strain was obtained by cross-induction. The virulence and protective efficacy of RA343 were subsequently assessed, and RA343 showed reduction of survival ability in RAW264.7 cells and low pathogenicity in the murine model in vivo. Immunization with RA343 elevated expression levels of IFN-γ and TNF-α and a robust T-cell immune response in mice. Guinea pigs were inoculated with RA343 at 1 × 10⁹ CFU for single and booster immunization. After the single immunization of RA343, about 60% of guinea pigs could resist the attack of M28 or 2308 strain. The secondary immunization in guinea pigs confer 80% and 70% protection against M28 or 2308 challenges, respectively. Then, the gene expression profile of RAW264.7 cells infected with Brucella abortus A19 or RA343 was analyzed by RNA-seq to investigate the cellular responses immediately after Brucella entry. The RNA-seq analysis revealed that a total of 14,549 genes were significantly regulated by Brucella 1 h postinfection. The differential gene expression was predominantly associated with innate immune responses and many inflammatory pathways, such as MAPK, JAK-STAT, and NF-κB signaling ones. Our findings suggest that the RA343 strain is a promising novel vaccine candidate to protect animals from B. abortus and Brucella melitensis infection. Meanwhile, this study serves as a new reference for investigating the immune regulatory mechanisms of rough Brucella.

Keywords

brucellosis / protective efficacy / RNA-seq analysis / vaccines

References

[1] M. P. Franco, M. Mulder, R. H. Gilman, and H. L. Smits, “Human Brucellosis,” Lancet Infectious Diseases7, no. 12 (2007): 775-786, https://doi.org/10.1016/s1473-3099(07)70286-4.

[2] N. C. Hull and B. A. Schumaker, “Comparisons of Brucellosis Between Human and Veterinary Medicine,” Infection Ecology & Epidemiology8, no. 1 (2018): 1500846, https://doi.org/10.1080/20008686.2018.1500846.

[3] S. Sun, H. Jiang, Q. Li, et al., “Safety and Transcriptome Analysis of Live Attenuated Brucella Vaccine Strain S2 on Non-Pregnant Cynomolgus Monkeys Without Abortive Effect on Pregnant Cynomolgus Monkeys,” Frontiers in Veterinary Science8 (2021): 641022, https://doi.org/10.3389/fvets.2021.641022.

[4] H. Jiang, D. O'Callaghan, and J. B. Ding, “Brucellosis in China: History, Progress and Challenge,” Infectious Diseases of Poverty9, no. 1 (2020): 55, https://doi.org/10.1186/s40249-020-00673-8.

[5] J. Djangwani, G. Ooko Abong, L. Gicuku Njue, and D. W. M. Kaindi, “Brucellosis: Prevalence With Reference to East African Community Countries - A Rapid Review,” Veterinary Medical Science7, no. 3 (2021): 851-867, https://doi.org/10.1002/vms3.425.

[6] Y. Wang, Y. Wang, L. Zhang, et al., “An Epidemiological Study of Brucellosis on Mainland China During 2004-2018,” Transboundary and Emerging Diseases68, no. 4 (2021): 2353-2363, https://doi.org/10.1111/tbed.13896.

[7] C. Kefaloudi, K. Mellou, G. Dougas, R. Vorou, K. Mitrou, and F. Kontopidou, “Human Brucellosis in Greece, 2005-2020: A Persistent Public Health Problem,” Vector Borne and Zoonotic Diseases22, no. 3 (2022): 163-169, https://doi.org/10.1089/vbz.2021.0050.

[8] P. Yagupsky, P. Morata, and J. D. Colmenero, “Laboratory Diagnosis of Human Brucellosis,” Clinical Microbiology Reviews33, no. 1 (2019), e00073-19, https://doi.org/10.1128/cmr.00073-19.

[9] M. X. Byndloss and R. M. Tsolis, “Brucella spp. Virulence Factors and Immunity,” Annual Review of Animal Biosciences4, no. 1 (2016): 111-127, https://doi.org/10.1146/annurev-animal-021815-111326.

[10] M. Golshani and S. Buozari, “A Review of Brucellosis in Iran: Epidemiology, Risk Factors, Diagnosis, Control, and Prevention,” Iranian Biomedical Journal21, no. 6 (2017): 349-359, https://doi.org/10.18869/acadpub.ibj.21.6.349.

[11] L. Zhu, Y. Feng, G. Zhang, et al., “Brucella suis Strain 2 Vaccine Is Safe and Protective Against Heterologous Brucella spp. Infections,” Vaccine34, no. 3 (2016): 395-400, https://doi.org/10.1016/j.vaccine.2015.09.116.

[12] H. Hou, X. Liu, and Q. Peng, “The Advances in Brucellosis Vaccines,” Vaccine37, no. 30 (2019): 3981-3988, https://doi.org/10.1016/j.vaccine.2019.05.084.

[13] G. G. Schurig, N. Sriranganathan, and M. J. Corbel, “Brucellosis Vaccines: Past, Present and Future,” Veterinary Microbiology90, no. 1-4 (2002): 479-496, https://doi.org/10.1016/s0378-1135(02)00255-9.

[14] M. Banai, “Control of Small Ruminant Brucellosis by Use of Brucella melitensis Rev.1 Vaccine: Laboratory Aspects and Field Observations,” Veterinary Microbiology90, no. 1-4 (2002): 497-519, https://doi.org/10.1016/s0378-1135(02)00231-6.

[15] P. M. Muñoz, R. Conde-Álvarez, S. Andrés-Barranco, et al., “A Brucella melitensis H38ΔwbkF Rough Mutant Protects Against Brucella ovis in Rams,” Veterinary Research53, no. 1 (2022): 16, https://doi.org/10.1186/s13567-022-01034-z.

[16] N. Jain-Gupta, S. G. Waldrop, N. M. Tenpenny, S. G. Witonsky, S. M. Boyle, and N. Sriranganathan, “Rough Brucella Neotomae Provides Protection Against Brucella suis Challenge in Mice,” Veterinary Microbiology239 (2019): 108447, https://doi.org/10.1016/j.vetmic.2019.108447.

[17] M. Mancilla, “Smooth to Rough Dissociation in Brucella: The Missing Link to Virulence,” Frontiers in Cellular and Infection Microbiology5 (2016), 98, https://doi.org/10.3389/fcimb.2015.00098.

[18] X. Peng, Y. Liu, Y. Qin, et al., “Comparative Transcriptome Analysis of Artificially Induced Rough-Mutant Brucella Strain RM57 and Its Parent Strain Brucella melitensis M1981,” Frontiers in Veterinary Science6 (2020), 459, https://doi.org/10.3389/fvets.2019.00459.

[19] R. Vemulapalli, J. R. McQuiston, G. G. Schurig, N. Sriranganathan, S. M. Halling, and S. M. Boyle, “Identification of an IS711 Element Interrupting the wboA Gene of Brucella abortus Vaccine Strain RB51 and a PCR Assay to Distinguish Strain RB51 From Other Brucella Species and Strains,” Clinical and Diagnostic Laboratory Immunology6, no. 5 (1999): 760-764, https://doi.org/10.1128/cdli.6.5.760-764.1999.

[20] I. Moriyón, M. J. Grilló, D. Monreal, et al., “Rough Vaccines in Animal Brucellosis: Structural and Genetic Basis and Present Status,” Veterinary Research35, no. 1 (2004): 1-38, https://doi.org/10.1051/vetres:2003037.

[21] Y. Feng, X. Peng, H. Jiang, Y. Peng, L. Zhu, and J. Ding, “Rough Brucella Strain RM57 Is Attenuated and Confers Protection Against Brucella melitensis,” Microbial Pathogenesis107 (2017): 270-275, https://doi.org/10.1016/j.micpath.2017.03.045.

[22] J. Lalsiamthara, N. Gogia, T. K. Goswami, R. K. Singh, and P. Chaudhuri, “Intermediate Rough Brucella abortus S19Δper Mutant Is DIVA Enable, Safe to Pregnant Guinea Pigs and Confers Protection to Mice,” Vaccine33, no. 22 (2015): 2577-2583, https://doi.org/10.1016/j.vaccine.2015.04.004.

[23] W. F. Ding Jiabo, H. Yang, W. Nan, et al., “Identification and Virulence Assessment for a Strain of Brucella abortus,” Scientia Agricultura Sinica47, no. 13 (2014): 2652-2658, https://link.cnki.net/urlid/10.3864/j.issn.0578-1752.2014.13.017.

[24] J. Ding, Y. Pan, H. Jiang, et al., “Whole Genome Sequences of Four Brucella Strains,” Journal of Bacteriology193, no. 14 (2011): 3674-3675, https://doi.org/10.1128/jb.05155-11.

[25] P. Wei, G. Cui, Q. Lu, et al., “A20 Promotes Brucella Intracellular Growth Via Inhibition of Macrophage Cell Death and Activation,” Veterinary Microbiology175, no. 1 (2015): 50-57, https://doi.org/10.1016/j.vetmic.2014.11.006.

[26] Y. Tian, W. Huang, J. Yang, et al., “Systematic Identification of Hepatitis E Virus ORF2 Interactome Reveals That TMEM134 Engages in ORF2-Mediated NF-κB Pathway,” Virus Research228 (2017): 102-108, https://doi.org/10.1016/j.virusres.2016.11.027.

[27] B. Wu, X. Chen, X. Pan, et al., “Single-Cell Transcriptome Analyses Reveal Critical Roles of RNA Splicing During Leukemia Progression,” PLoS Biology21, no. 5 (2023): e3002088, https://doi.org/10.1371/journal.pbio.3002088.

[28] J. Luo, D. Xue, F. Song, X. Liu, W. Li, and Y. Wang, “DUSP5 (Dual-Specificity Protein Phosphatase 5) Suppresses BCG-Induced Autophagy via ERK 1/2 Signaling Pathway,” Molecular Immunology126 (2020): 101-109, https://doi.org/10.1016/j.molimm.2020.07.019.

[29] L. D. Estrada, D. Ağaç Çobanoğlu, A. Wise, R. W. Maples, M. C. Çobanoğlu, and J. D. Farrar, “Adrenergic Signaling Controls Early Transcriptional Programs During CD8+ T Cell Responses to Viral Infection,” PLoS One17, no. 8 (2022): e0272017, https://doi.org/10.1371/journal.pone.0272017.

[30] M. Salmon-Divon and D. Kornspan, “Transcriptomic Analysis of Smooth Versus Rough Brucella melitensis Rev.1 Vaccine Strains Reveals Insights Into Virulence Attenuation,” International Journal of Medical Microbiology310, no. 1 (2020): 151363, https://doi.org/10.1016/j.ijmm.2019.151363.

[31] G. G. Schurig, R. M. Roop 2nd, T. Bagchi, S. Boyle, D. Buhrman, and N. Sriranganathan, “Biological Properties of RB51: A Stable Rough Strain of Brucella abortus,” Veterinary Microbiology28, no. 2 (1991): 171-188, https://doi.org/10.1016/0378-1135(91)90091-s.

[32] M. Rahmanpour, F. Keramat, S. Jourghasemi, et al., “Direct Correlation Between Th1 and Th17 Responses in Immunity to Brucella Infection,” Microbes and Infection21, no. 10 (2019): 441-448, https://doi.org/10.1016/j.micinf.2019.05.002.

[33] M. A. Vitry, C. De Trez, S. Goriely, et al., “Crucial Role of Gamma Interferon-Producing CD4+ Th1 Cells But Dispensable Function of CD8+ T Cell, B Cell, Th2, and Th17 Responses in the Control of Brucella melitensis Infection in Mice,” Infection and Immunity80, no. 12 (2012): 4271-4280, https://doi.org/10.1128/iai.00761-12.

[34] M. G. Rittig, A. Kaufmann, A. Robins, et al., “Smooth and Rough Lipopolysaccharide Phenotypes of Brucella Induce Different Intracellular Trafficking and Cytokine/Chemokine Release in Human Monocytes,” Journal of Leukocyte Biology74, no. 6 (2003): 1045-1055, https://doi.org/10.1189/jlb.0103015.

[35] E. M. Dorneles, G. K. Lima, A. Teixeira-Carvalho, et al., “Immune Response of Calves Vaccinated With Brucella abortus S19 or RB51 and Revaccinated With RB51,” PLoS One10, no. 9 (2015): e0136696, https://doi.org/10.1371/journal.pone.0136696.

[36] G. Zhang, J. Wang, Z. Zhao, et al., “Regulated Necrosis, a Proinflammatory Cell Death, Potentially Counteracts Pathogenic Infections,” Cell Death & Disease13, no. 7 (2022): 637, https://doi.org/10.1038/s41419-022-05066-3.

[37] F. M. Marim, M. M. C. Franco, M. T. R. Gomes, M. C. Miraglia, G. H. Giambartolomei, and S. C. Oliveira, “The Role of NLRP3 and AIM2 in Inflammasome Activation During Brucella abortus Infection,” Seminars in Immunopathology39, no. 2 (2017): 215-223, https://doi.org/10.1007/s00281-016-0581-1.

[38] H. Yeo, Y. H. Lee, D. Koh, Y. Lim, and S. Y. Shin, “Chrysin Inhibits NF-κB-Dependent CCL5 Transcription by Targeting IκB Kinase in the Atopic Dermatitis-Like Inflammatory Microenvironment,” International Journal of Molecular Sciences21, no. 19 (2020): 7348, https://doi.org/10.3390/ijms21197348.

[39] Z. Zhang, J. L. Bryan, E. DeLassus, L. W. Chang, W. Liao, and L. J. Sandell, “CCAAT/Enhancer-Binding Protein β and NF-κB Mediate High Level Expression of Chemokine Genes CCL3 and CCL4 by Human Chondrocytes in Response to IL-1β,” Journal of Biological Chemistry285, no. 43 (2010): 33092-33103, https://doi.org/10.1074/jbc.M110.130377.

[40] J. Pei, J. E. Turse, and T. A. Ficht, “Evidence of Brucella abortus OPS Dictating Uptake and Restricting NF-kappaB Activation in Murine Macrophages,” Microbes and Infection10, no. 6 (2008): 582-590, https://doi.org/10.1016/j.micinf.2008.01.005.

[41] F. Wang, S. Hu, W. Liu, Z. Qiao, Y. Gao, and Z. Bu, “Deep-Sequencing Analysis of the Mouse Transcriptome Response to Infection With Brucella melitensis Strains of Differing Virulence,” PLoS One6, no. 12 (2011): e28485, https://doi.org/10.1371/journal.pone.0028485.

[42] H. Hu, M. Tian, P. Li, et al., “Brucella Infection Regulates Thioredoxin-Interacting Protein Expression to Facilitate Intracellular Survival by Reducing the Production of Nitric Oxide and Reactive Oxygen Species,” Journal of Immunology204, no. 3 (2020): 632-643, https://doi.org/10.4049/jimmunol.1801550.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Research and One Health published by John Wiley & Sons Australia, Ltd on behalf of Institute of Animal Science, Chinese Academy of Agricultural Sciences.